469 related articles for article (PubMed ID: 36276096)
1. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set.
Liu H; Tang T
Front Oncol; 2022; 12():952290. PubMed ID: 36276096
[TBL] [Abstract][Full Text] [Related]
2. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
Zhou C; Li C; Zheng Y; Huang X
Front Oncol; 2022; 12():934076. PubMed ID: 36387247
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer profiles of the cuproptosis gene set.
Liu H
Am J Cancer Res; 2022; 12(8):4074-4081. PubMed ID: 36119826
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer genetic analysis of disulfidptosis-related gene set.
Liu H; Tang T
Cancer Genet; 2023 Nov; 278-279():91-103. PubMed ID: 37879141
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
Front Genet; 2022; 13():939956. PubMed ID: 36105090
[No Abstract] [Full Text] [Related]
7. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
[TBL] [Abstract][Full Text] [Related]
8. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression.
Zhao Q; Qi T
Front Oncol; 2023; 13():1117164. PubMed ID: 36925927
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related lncRNAs ovarian cancer: Multi-omics analysis of molecular mechanisms and potential therapeutic targets.
Wang Y; Liang Q; Xu L; Xiong J; Gao K; Xu P; Huang W
Environ Toxicol; 2024 Mar; 39(3):1650-1665. PubMed ID: 38019212
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
Front Genet; 2022; 13():923737. PubMed ID: 35991547
[No Abstract] [Full Text] [Related]
11. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
Yang Q; Zeng S; Liu W
PeerJ; 2023; 11():e15019. PubMed ID: 36949759
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis of single-cell and bulk RNA seq to reveal the prognostic model and tumor microenvironment remodeling mechanisms of cuproptosis-related genes in colorectal cancer.
Chu B; Wang Y; Yang J; Dong B
Aging (Albany NY); 2023 Dec; 15(23):14422-14444. PubMed ID: 38078879
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
15. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
16. High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases.
Li L; Li L; Sun Q
BMC Bioinformatics; 2022 Aug; 23(1):350. PubMed ID: 35996075
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
Yao Y; Chen H; Lou M; Chen T
Front Genet; 2023; 14():1071694. PubMed ID: 36755576
[No Abstract] [Full Text] [Related]
19. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma.
Chen Y; Zou X; Ma M; Liu Y; Wang R; Dai Z; Tashiheng Y; Yan Y; Yu X; Wang X; Liu C; Lin X; Cheng H
Curr Oncol; 2023 Jan; 30(2):1648-1662. PubMed ID: 36826087
[TBL] [Abstract][Full Text] [Related]
20. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
